Neurotrophic keratopathy: Clinical presentation and effects of cenegermin.
Cenegermin
Nerve growth factor
Neurotrophic keratopathy
Journal
American journal of ophthalmology case reports
ISSN: 2451-9936
Titre abrégé: Am J Ophthalmol Case Rep
Pays: United States
ID NLM: 101679941
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
08
11
2021
revised:
08
03
2022
accepted:
09
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
To report on 4 patients (3 adults, 1 child) with neurotrophic keratopathy (NK) treated with cenegermin 20 μg/ml (Oxervate®), a recombinant human nerve growth factor (rhNGF), which was authorized by the European Medicines Agency for the treatment of neurotrophic keratopathy stage 2 and stage 3 of Mackie Classification in patients over 18 years of age. Three patients with neurotrophic keratopathy stage 2 and 1 patient with neurotrophic keratopathy stage 3, who were treated with cenegermin eye drops 6 times daily for 8 weeks, were observed. Two patients suffered from herpetic keratitis and 2 patients from neurotrophic keratopathy secondary to orbital radiation. In addition to closure of epithelial defects, an increase of corneal sensitivity and improvement of visual acuity has been shown in all treated patients at the end of therapy. One patient reported on neuralgic pain as a side effect. The corneal epithelium remained closed during the follow-up period of 11 weeks, 31 and 32 months after cessation of therapy in 3 patients, respectively. In one patient, corneal erosion recurred 4 weeks after completion of treatment due to recurrent HSV keratitis, which resolved after therapy adjustment and the corneal epithelium remained closed for 35 weeks. The cases presented suggest that treatment with cenegermin 20 μg/ml not only promotes corneal epithelial wound healing, but also significantly improves corneal sensitivity and visual acuity with minor side effects in adults and children.
Identifiants
pubmed: 35330588
doi: 10.1016/j.ajoc.2022.101488
pii: S2451-9936(22)00234-1
pmc: PMC8938625
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101488Informations de copyright
© 2022 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The following authors have no financial disclosures: JB, AG, NP, JP. All authors attest that they met the current ICMJE criteria.
Références
Ophthalmology. 2005 May;112(5):888-95
pubmed: 15878072
Saudi J Ophthalmol. 2014 Jul;28(3):168-72
pubmed: 25278792
Clin Ophthalmol. 2014 Mar 19;8:571-9
pubmed: 24672223
Eye Brain. 2018 Jun 28;10:37-45
pubmed: 29988739
Drugs. 2020 Apr;80(5):489-494
pubmed: 32185680
Curr Opin Ophthalmol. 1999 Aug;10(4):270-6
pubmed: 10621535
Ocul Surf. 2018 Apr;16(2):218-225
pubmed: 29305292
Ophthalmology. 2018 Sep;125(9):1332-1343
pubmed: 29653858
Science. 1987 Sep 4;237(4819):1154-62
pubmed: 3306916
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4695-4702
pubmed: 28910445
Graefes Arch Clin Exp Ophthalmol. 2014 Nov;252(11):1779-87
pubmed: 25078353
Arch Soc Esp Oftalmol. 2013 Aug;88(8):302-6
pubmed: 23886361
Nature. 2013 Jan 17;493(7432):306
pubmed: 23325208
Br J Ophthalmol. 2000 Aug;84(8):826-33
pubmed: 10906085
Am J Physiol Cell Physiol. 2018 Nov 1;315(5):C757-C765
pubmed: 30257104
Ophthalmology. 2020 Jan;127(1):14-26
pubmed: 31585826
Prog Retin Eye Res. 2018 Sep;66:107-131
pubmed: 29698813
Cornea. 2019 Nov;38(11):1450-1452
pubmed: 31403527
Sci Rep. 2018 Aug 1;8(1):11526
pubmed: 30069058
Acta Ophthalmol. 2019 Mar;97(2):137-145
pubmed: 30225941
Exp Eye Res. 2003 May;76(5):521-42
pubmed: 12697417
Biomed Res Int. 2015;2015:805876
pubmed: 26451380